Simone Susanne Krebs, M.D., M.S.

Peer-Reviewed Articles

1. Grkovski M, Krebs SS, O'Donoghue JA, Kuten J, Mauguen A, Shobeiri P, Lafontaine D, Thor M, Augensen F, Fox JJ, Pandit-Taskar N, Dunphy MP, Bodei L, Humm JL, Schoder H. Lesion Absorbed Dose-Response Relationship in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [(177)Lu]Lu-PSMA-617 Radiopharmaceutical Therapy. J Nucl Med, 2025. e-Pub 2025. PMID: 40774698.
2. Gajecki L, Lebedeva IV, Liao YR, Ambriz D, Carter LM, Kumpf M, Lovibond S, Hachey JS, Graham MS, Postow MA, Lewis JS, Andrew DP, Baca M, Schöder H, Larson S, Veach DR, Krebs S. IL13Rα2-Targeting Antibodies for Immuno-PET in Solid Malignancies. J Nucl Med 66(4):605-611, 2025. e-Pub 2025. PMID: 39978817.
3. Lafontaine D, Augensen F, Kesner A, Vincent R, Kirov AS, Krebs S, Schöder H, Humm JL. Machine-learning based quantification of lung shunt fraction from 99mTc-MAA SPECT/CT for selective internal radiation therapy of liver tumors using TriDFusion (3DF). EJNMMI Physics 12(1):22, 2025. e-Pub 2025. PMID: 40064717.
4. Imber BS, Yu KKH, Abida W, Pike LRG, Grkovski M, Kaley TJ, Morris MJ, Bodei L, Nosov A, Dunphy MPS, Schoder H, Fox JJ, Rosenblum M, Bale T, Krebs S. Symptomatic Prostate-Specific Membrane Antigen PET-Positive Radionecrosis After Multimodality Brain Metastasis-Directed Treatment Including [(177)Lu]Lu-PSMA-617. J Nucl Med 66(7):1153-1154, 2025. e-Pub 2025. PMID: 40049744.
5. Vaughn BA, Lee SG, Vargas DB, Seo S, Rinne SS, Xu H, Guo HF, Le Roux AB, Gajecki L, Krebs S, Yang G, Ouerfelli O, Zanzonico PB, Fung EK, St Jean S, Carrasco SE, Jungbluth A, Cheung NKV, Larson SM, Veach DR, Cheal SM. Theranostic GPA33-Pretargeted Radioimmunotherapy of Human Colorectal Carcinoma with a Bivalent (177)Lu-Labeled Radiohapten. J Nucl Med 65(10):1611-1618, 2024. e-Pub 2024. PMID: 39168519.
6. Pasquini L, Jenabi M, Graham M, Peck KK, Schoder H, Holodny AI, Krebs S. Tumors Affect the Metabolic Connectivity of the Human Brain Measured by 18 F-FDG PET. Clin Nucl Med 49(9):822-829, 2024. e-Pub 2024. PMID: 38693648.
7. Kurtz K, Eibler L, Dacek MM, Carter LM, Veach DR, Lovibond S, Reynaud E, Qureshy S, McDevitt MR, Bourne C, Monette S, Punzalan B, Khayat S, Verma S, Kesner AL, Cheung NV, Schoder H, Gajecki L, Cheal SM, Larson SM, Scheinberg DA, Krebs S. Engineering CAR-T cells for radiohapten capture in imaging and radioimmunotherapy applications. Theranostics 13(15):5469-5482, 2023. e-Pub 2023. PMID: 37908719.
8. McLaughlin LA, Yildirim O, Rosenblum MK, Imber BS, Haseltine JM, Zelefsky MJ, Schoder H, Morris MJ, Rafelson WM, Krebs S, Moss NS. Identification of incidental brain tumors in prostate cancer patients via PSMA PET/CT. J Neurooncol 163(2):455-462, 2023. e-Pub 2023. PMID: 37247180.
9. Carter LM, Krebs S, Marquis H, Ocampo Ramos JC, Olguin EA, Mason EO, Bolch WE, Zanzonico PB, Kesner AL. Dosimetric variability across a library of computational tumor phantoms. J Nucl Med 64(5):782-790, 2023. e-Pub 2023. PMID: 37074039.
10. Bodei L, Raj N, Do RK, Mauguen A, Krebs S, Reidy-Lagunes D, Schoder H. Interim Analysis of a Prospective Validation of 2 Blood-Based Genomic Assessments (PPQ and NETest) to Determine the Clinical Efficacy of (177)Lu-DOTATATE in Neuroendocrine Tumors. J Nucl Med 64(4):567-573, 2023. e-Pub 2023. PMID: 36396457.
11. Krebs S, Schwartz J, Grommes C, Young RJ, Schoder H, Mayerhoefer ME. Detecting CXCR4 Expression in Meningioma on (68)Ga-Pentixafor PET/MRI. J Nucl Med 64(4):667-668, 2023. e-Pub 2023. PMID: 36357178.
12. Sponagel J, Jones JK, Frankfater C, Zhang S, Tung O, Cho K, Tinkum KL, Gass H, Nunez E, Spitz DR, Chinnaiyan P, Schaefer J, Patti GJ, Graham MS, Mauguen A, Grkovski M, Dunphy MP, Krebs S, Luo J, Rubin JB, Ippolito JE. Sex differences in brain tumor glutamine metabolism reveal sex-specific vulnerabilities to treatment. Med 3(11):792-811.e12, 2022. e-Pub 2022. PMID: 36108629.
13. Lafontaine D, Schmidtlein CR, Kirov A, Reddy RP, Krebs S, Schoder H, Humm JL. TriDFusion (3DF) image viewer. EJNMMI Phys 9(1):72, 2022. e-Pub 2022. PMID: 36258098.
14. Imber BS, Young RJ, Beal K, Reiner AS, Giantini-Larsen AM, Krebs S, Yang JT, Aramburu-Nunez D, Cohen GN, Brennan C, Tabar V, Moss NS. Salvage resection plus cesium-131 brachytherapy durably controls post-SRS recurrent brain metastases. J Neurooncol 159(3):609-618, 2022. e-Pub 2022. PMID: 35896906.
15. Krebs S, Grommes C, McDevitt MR, Carlin SD, O'Donoghue JA, Graham MS, Young RJ, Schoder H, Gutin PH, Bander NH, Osborne JR. [(89)Zr]Zr-huJ591 immuno-PET targeting PSMA in IDH mutant anaplastic oligodendroglioma. Eur J Nucl Med Mol Imaging 49(2):783-785, 2022. e-Pub 2022. PMID: 34498111.
16. Krebs S, Mauguen A, Yildirim O, Hatzoglou V, Francis JH, Schaff LR, Mellinghoff IK, Schoder H, Grommes C. Prognostic value of [(18)F]FDG PET/CT in patients with CNS lymphoma receiving ibrutinib-based therapies. Eur J Nucl Med Mol Imaging 48(12):3940-3950, 2021. e-Pub 2021. PMID: 33966087.
17. Dacek MM, Veach DR, Cheal SM, Carter LM, McDevitt MR, Punzalan B, Burnes Vargas D, Kubik TZ, Monette S, Santich BH, Yang G, Ouerfelli O, Kesner AL, Cheung NV, Scheinberg DA, Larson SM, Krebs S. Engineered Cells as a Test Platform for Radiohaptens in Pretargeted Imaging and Radioimmunotherapy Applications. Bioconjug Chem 32(4):649-654, 2021. e-Pub 2021. PMID: 33819023.
18. Carter LM, Choi C, Krebs S, Beattie BJ, Kim CH, Schoder H, Bolch WE, Kesner AL. Patient Size-Dependent Dosimetry Methodology Applied to (18)F-FDG Using New ICRP Mesh Phantoms. J Nucl Med 62(12):1805-14, 2021. e-Pub 2021. PMID: 33863823.
19. Krebs S, O'Donoghue JA, Biegel E, Beattie BJ, Reidy D, Lyashchenko SK, Lewis JS, Bodei L, Weber WA, Pandit-Taskar N. Comparison of (68)Ga-DOTA-JR11 PET/CT with dosimetric (177)Lu-satoreotide tetraxetan ((177)Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 47(13):3047-3057, 2020. e-Pub 2020. PMID: 32378020.
20. Krebs S, Veach DR, Carter LM, Grkovski M, Fornier M, Mauro MJ, Voss MH, Danila DC, Burnazi E, Null M, Staton K, Pressl C, Beattie BJ, Zanzonico P, Weber WA, Lyashchenko SK, Lewis JS, Larson SM, Dunphy MPS. First-in-Humans Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted PET. J Nucl Med 61(11):1580-1587, 2020. e-Pub 2020. PMID: 32169913.
21. Krebs S, Petkovska I, Ho AL, Ulaner GA. Laboratory-Proven Asymptomatic SARS-CoV-2 (COVID-19) Infection on 18F-FDG PET/CT. Clin Nucl Med 45(8):654-655, 2020. e-Pub 2020. PMID: 32433161.
22. Graham MS, Krebs S, Bale T, Domfe K, Lobaugh SM, Zhang Z, Dunphy MP, Kaley T, Young RJ. Value of [(18)F]-FDG positron emission tomography in patients with recurrent glioblastoma receiving bevacizumab. Neurooncol Adv 2(1):vdaa050, 2020. e-Pub 2020. PMID: 32642703.
23. Grkovski M, Goel R, Krebs S, Staton KD, Harding JJ, Mellinghoff IK, Humm JL, Dunphy MPS. Pharmacokinetic Assessment of (18)F-(2S,4R)-4-Fluoroglutamine in Patients with Cancer. J Nucl Med 61(3):357-366, 2020. e-Pub 2020. PMID: 31601700.
24. Reidy-Lagunes D, Pandit-Taskar N, O'Donoghue JA, Krebs S, Staton KD, Lyashchenko SK, Lewis JS, Raj N, Gonen M, Lohrmann C, Bodei L, Weber WA. Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist (177)Lu-Satoreotide Tetraxetan. Clin Cancer Res 25(23):6939-6947, 2019. e-Pub 2019. PMID: 31439583.
25. Krebs S, Pandit-Taskar N, Reidy D, Beattie BJ, Lyashchenko SK, Lewis JS, Bodei L, Weber WA, O'Donoghue JA. Biodistribution and radiation dose estimates for (68)Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors. Eur J Nucl Med Mol Imaging 46(3):677-685, 2019. e-Pub 2019. PMID: 30374529.
26. Eskreis-Winkler S, Corrias G, Monti S, Zheng J, Capanu M, Krebs S, Fung M, Reeder S, Mannelli L. IDEAL-IQ in an oncologic population: meeting the challenge of concomitant liver fat and liver iron. Cancer Imaging 18(1):51, 2018. e-Pub 2018. PMID: 30541635.
27. Krebs S, Ahad A, Carter LM, Eyquem J, Brand C, Bell M, Ponomarev V, Reiner T, Meares CF, Gottschalk S, Sadelain M, Larson SM, Weber WA. Antibody with Infinite Affinity for In Vivo Tracking of Genetically Engineered Lymphocytes. J Nucl Med 59(12):1894-1900, 2018. e-Pub 2018. PMID: 29903928.
28. Corrias G, Krebs S, Eskreis-Winkler S, Ryan D, Zheng J, Capanu M, Saba L, Monti S, Fung M, Reeder S, Mannelli L. MRI liver fat quantification in an oncologic population: the added value of complex chemical shift-encoded MRI. Clin Imaging 52:193-199, 2018. e-Pub 2018. PMID: 30103108.
29. Krebs S, Ganly I, Ghossein R, Yang J, Yahalom J, Schoder H. Solitary Extramedullary Plasmacytoma of the Cricoid Cartilage-Case Report. Front Oncol 7:284, 2017. e-Pub 2017. PMID: 29230383.
30. Krebs S, Monti S, Lewis N, Luciano A, Rastrelli L, Mannelli L. Lower-Extremity Pseudomyogenic Hemangioendothelioma on Bone Scintigraphy and PET/CT. Clin Nucl Med 42(5):383-385, 2017. e-Pub 2017. PMID: 28288045.
31. Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai SA, Wakefield A, Fousek K, Bielamowicz K, Chow KK, Brawley VS, Byrd TT, Krebs S, Gottschalk S, Wels WS, Baker ML, Dotti G, Mamonkin M, Brenner MK, Orange JS, Ahmed N. Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape. J Clin Invest 126(8):3036-52, 2016. e-Pub 2016. PMID: 27427982.
32. Krebs S, Monti S, Seshan S, Fox J, Mannelli L. IgG4-Related Kidney Disease in a Patient With History of Breast Cancer: Findings on 18F-FDG PET/CT. Clin Nucl Med 41(8):e388-9, 2016. e-Pub 2016. PMID: 27187735.
33. Krenciute G, Krebs S, Torres D, Wu MF, Liu H, Dotti G, Li XN, Lesniak MS, Balyasnikova IV, Gottschalk S. Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Ralpha2-positive Glioma. Mol Ther 24(2):354-363, 2016. e-Pub 2016. PMID: 26514825.
34. Krebs S, Chow KK, Yi Z, Rodriguez-Cruz T, Hegde M, Gerken C, Ahmed N, Gottschalk S. T cells redirected to interleukin-13Ralpha2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Ralpha1. Cytotherapy 16(8):1121-31, 2014. e-Pub 2014. PMID: 24841514.
35. Wild D, Fani M, Fischer R, Del Pozzo L, Kaul F, Krebs S, Fischer R, Rivier JE, Reubi JC, Maecke HR, Weber WA. Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study. J Nucl Med 55(8):1248-52, 2014. e-Pub 2014. PMID: 24963127.
36. Hegde M, Corder A, Chow KK, Mukherjee M, Ashoori A, Kew Y, Zhang YJ, Baskin DS, Merchant FA, Brawley VS, Byrd TT, Krebs S, Wu MF, Liu H, Heslop HE, Gottschalk S, Yvon E, Ahmed N. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther 21(11):2087-101, 2013. e-Pub 2013. PMID: 23939024.
37. Krebs S, Trippel M, Prokop T, Omer, TN, Landwehrmeyer B, Weber B, Nikkah, G. Immune response after striatal engraftment of fetal neuronal cells in patients with Huntington's disease: Consequences for cerebral transplantation programs. Clin Exp Neuroimmunol 2(2):25-32, 2011. e-Pub 2011.
38. Krebs S, Omer B, Omer TN, Fliser D. Wormwood (Artemisia absinthium) for poorly responsive early-stage IgA nephropathy: a pilot uncontrolled trial. Am J Kidney Dis 56(6):1095-9, 2010. e-Pub 2010. PMID: 20843592.
39. Krebs S, Omer TN, Omer B. Wormwood (Artemisia absinthium) suppresses tumour necrosis factor alpha and accelerates healing in patients with Crohn's disease - A controlled clinical trial. Phytomedicine 17(5):305-9, 2010. e-Pub 2010. PMID: 19962291.
40. Omer B, Krebs S, Omer H, Noor TO. Steroid-sparing effect of wormwood (Artemisia absinthium) in Crohn's disease: a double-blind placebo-controlled study. Phytomedicine 14(2-3):87-95, 2007. e-Pub 2007. PMID: 17240130.

Review Articles

1. Morris ZS, Demaria S, Monjazeb AM, Formenti SC, Weichselbaum RR, Welsh J, Enderling H, Schoenfeld JD, Brody JD, McGee HM, Mondini M, Kent MS, Young KH, Galluzzi L, Karam SD, Theelen WSME, Chang JY, Huynh MA, Daib A, Pitroda S, Chung C, Serre R, Grassberger C, Deng J, Sodji QH, Nguyen AT, Patel RB, Krebs S, Kalbasi A, Kerr C, Vanpouille-Box C, Vick L, Aguilera TA, Ong IM, Herrera F, Menon H, Smart D, Ahmed J, Gartrell RD, Roland CL, Fekrmandi F, Chakraborty B, Bent EH, Berg TJ, Hutson A, Khleif S, Sikora AG, Fong L. Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation. Lancet Oncol 26(3):e152-e170, 2025. e-Pub 2025. PMID: 40049206.
2. Glaviano A, Lau HH, Carter LM, Lee EC, Lam HY, Okina E, Tan DJ, Tan W, Ang HL, Carbone D, Yee MH, Shanmugam MK, Huang XZ, Sethi G, Tan TZ, Lim LH, Huang RJ, Ungefroren H, Giovannetti E, Tang DG, Bruno TC, Luo P, Andersen MH, Qian BZ, Ishihara J, Radisky DC, Elias S, Yadav S, Kim M, Robert C, Diana P, Schalper K, Shi T, Merghoub T, Krebs S, Kusumbe AP, Davids MS, Brown JR, Kumar AP. Harnessing the tumor microenvironment. J Hematol Oncol 18(1), 2025. e-Pub 2025. PMID: 39806516.
3. Lovibond S, Gewirtz AN, Pasquini L, Krebs S, Graham MS. The promise of metabolic imaging in diffuse midline glioma. Neoplasia 39:100896, 2023. e-Pub 2023. PMID: 36944297.
4. Krebs S, Barasch JG, Young RJ, Grommes C, Schoder H. Positron emission tomography and magnetic resonance imaging in primary central nervous system lymphoma-a narrative review. Ann Lymphoma 5, 2021. e-Pub 2021. PMID: 34223561.
5. Krebs S, Dacek MM, Carter LM, Scheinberg DA, Larson SM. CAR Chase: Where Do Engineered Cells Go in Humans?. Front Oncol 10:577773, 2020. e-Pub 2020. PMID: 33042849.
6. Krebs S, Gottschalk S. Cell carriers to attack glioma. Cytotherapy 16(7):871-2, 2014. e-Pub 2014. PMID: 24910384.
7. Krebs S, Rodriguez-Cruz TG, Derenzo C, Gottschalk S. Genetically modified T cells to target glioblastoma. Front Oncol 3:322, 2013. e-Pub 2013. PMID: 24427741.

Abstracts

1. Imber B, Jackson C, Young R, Humm J, Grkovski M, Bale T, Miller A, Mellinghoff I, Krebs S, Schoder H, Kaley T. A prospective phase I study of adjuvant [177Lu]Lu-PSMA-617 for PSMA-expressing IDH wildtype gliomas following chemoradiotherapy. Nuclear Medicine and Neurooncology Symposium: Precision Medicine:46, 2025. e-Pub 2025.
2. Jenabi M, Pasquini L, Gunjan Shah, Mailankody S, Scordo M, Landau H, Rajeeve S, Lesokhin S, Hashmi H, Perica K, Hultcrantz M, Korde N, Shah U, Tan C, Hassoun H, Usmani S, Giralt S, Santomasso B, Holodny A, Krebs S. Investigating metabolic connectivity in patients with multiple myeloma receiving BCMA CAR T cell therapy. American Society of Clinical Oncology Annual Meeting 43(16_Suppl):7524, 2025. e-Pub 2025.
3. Imber B, Kwok Hei Yu K, Abida W, Pike L, Grkovski M, Kaley T, Morris M, Bodei L, Nosov A, Dunphy M, Schoder H, Fox J, Rosenblum M, Bale T, Krebs S. Symptomatic prostate-specific membrane antigen (PSMA) PET-positive radionecrosis following multimodality brain metastasis-directed treatment including [177Lu]Lu-PSMA-617. Nuclear Medicine and Neurooncology Symposium: Precision Medicine:29, 2025. e-Pub 2025.
4. Mirzaei HR, Lovibond S, Gajecki L, Qureshy S, Kumpf M, Jeanjean P, Lee SG, Cai W, Miranda I, Mauguen A, Carter L, Schöder H, Veach DR, Scheinberg DA, Krebs S. Longitudinal in vivo tracking of novel human anti-IL13Rα2-scFv-derived CAR-T cells using radiohapten capture. Preclinical Imaging Consortium, 2025. e-Pub 2025.
5. Qureshy S, Gajecki L, Veach D, Lee SG, Matei I, Carter L, Lyden D, Scheinberg D, Krebs S. Utilizing CAR T cell-derived exosomes for radiotheranostic applications. American Association for Cancer Research Annual Meeting 85(8_Suppl_1):Abstract nr 585, 2025. e-Pub 2025.
6. Qureshy S, Gajecki L, Veach D, Matei I, Lee SG, Carter, Lyden D, Scheinberg D, Krebs S. Engineering CAR T Cell Exosomes for Tumor-Specific Delivery of Imaging and Therapeutic Radionuclides. European Molecular Imaging Meeting, 2025. e-Pub 2025.
7. Jeanjean P, Kumpf M, Lovibond S, Gajecki L, Veach DR, Krebs S. Interleukin-13 Receptor Alpha 2-targeted ImmunoPET in Sarcoma. European Molecular Imaging Meeting, 2025. e-Pub 2025.
8. Gajecki, L, Lebedeva I, Ambriz D, Lovibond S, Veach D, Jungbluth A, Carter L, Schoder H, Larson S, Krebs S. Novel IL13Rα2-targeting antibodies for immunoPET in glioblastoma. European Molecular Imaging Meeting, 2024. e-Pub 2024.
9. Eibler L, Kurtz KG, Dacek MM, Carter LM, Lovibond S, Reynaud E, Veach DR, Qureshy S, McDevitt MR, Bourne C, Monette S, Punzalan B, Khayat S, Verma S, Cheung NK, Kesner AL, Schöder H, Cheal SM, Scheinberg DA, Larson SM, Krebs S. A novel image-guided CAR T-cell approach for delivery of α-radionuclides to enhance anti-tumor killing efficacy in lymphoma. European Molecular Imaging Meeting, 2023. e-Pub 2023.
10. Kurtz K, Eibler L, Dacek M, Carter LM, Cheal S, Veach DR, Qureshy SA, Han J, Reynaud E, Verma S, McDevitt M, Punzalan B, Vargas DB, Santich BH, Monette S, Kesner A, Cheung NK, Larson S, Scheinberg DA, Krebs S. A radiohapten capture system for CAR T cells that tracks them in vivo and improves efficacy. 34th EORTC-NCI-AACR Symposium 174(Suppl 1):S3, 2022. e-Pub 2022.
11. Eibler L, Kurtz K, Dacek M, Carter L, Cheal S, Veach D, Qureshy S, Han J, Reynaud E, Verma S, McDevitt M, Punzalan B, Burnes Vargas D, Santich B, Monette S, Kesner A, Cheung N-K, Scheinberg D, Larson S, Krebs S. A humanized anti-benzyl-DOTA single chain variable fragment for in vivo tracking of CD19 CART cells. Society of Nuclear Medicine and Molecular Imaging Annual Meeting 63(Suppl 2), 2022. e-Pub 2022.
12. Krebs S. Comparison of 68Ga-DOTA-JR11 PET/CT with Dosimetric 177Lu-satoreotide Tetraxetan (177Lu-DOTA-JR11) SPECT/CT in Patients with Metastatic Neuroendocrine Tumors Undergoing Peptide Receptor Radionuclide Therapy. Third International Conference on Medical Imaging and Case Reports 6(1):S4, 2022. e-Pub 2022.
13. Dacek M, Cheal S, Veach D, Qureshy S, Carter L, Eibler L, Verma S, Mcdevitt M, Punzalan B, Burnes Vargas D, Santich B, Kesner A, Cheung N-K, Scheinberg D, Larson S, Krebs S. Characterization of a novel radiohapten capture system in CAR T cells for tracking in vivo and improving CAR T efficacy. International Conference on Lymphocyte Engineering 33(7-8):A6, 2022. e-Pub 2022.
14. Eibler L, Kurtz KG, Dacek MM, Carter LM, Cheal SM, Veach DR, Qureshy S, Han J, Reynaud E, Verma S, McDevitt MR, Punzalan B, Burnes Vargas D, Santich BH, Monette S, Kesner AL, Cheung NK, Scheinberg DA, Larson SM, Krebs S. Optimizing a humanized DOTA single chain variable fragment reporter platform for in vivo CAR T cell tracking. European Molecular Imaging Meeting, 2022. e-Pub 2022.
15. Dacek MM, Kurtz KG, Cheal SM, Veach DR, Qureshy S, Carter LM, Han J, Verma S, McDevitt MR, Punzalan B, Burnes Vargas D, Santich BH, Kesner AL, Cheung NK, Scheinberg DA, Larson SM, Krebs S. Assessing the impact of structural differences in CAR T Cell reporter gene design on performance. World Molecular Imaging Congress, 2021. e-Pub 2021.
16. Krebs S, Graham MS, Grkovski M, Mauguen A, Goel R, Thakur SB, Schaf LR, Mellinghof IK, Young RJ, Kaley T, Dunphy MP. 18F-Fluoroglutamine PET as a Promising Prognostic Tool in IDH Mutant Glioma. Annual Congress of the European Association of Nuclear Medicine 48(Suppl 1):S298, 2021. e-Pub 2021. PMID: 34559267.
17. Krebs S, Dacek MM, Cheal SM, Veach DR, Carter LM, Verma S, Santich B, Punzalan B, Burnes Vargas D, Kesner AL, Cheung NK, Scheinberg DA, Larson SM. Cell surface-anchored humanized anti-DOTA scFv for tracking CD19 CAR T cells. World Molecular Imaging Conference Virtual, 2020. e-Pub 2020.
18. Krebs S, O'Donoghue J, Biegle E, Beattie BJ, Reidy D, Bodei L, Weber WA, Pandit-Taskar N. Comparison of 68Ga-DOTA-JR11 PET/CT with (dosimetric) 177Lu-DOTA-JR11 SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy. Annual Congress of the European Association of Nuclear Medicine 45(Suppl 1):S63-S64, 2018. e-Pub 2018.
19. Krebs S, Dunphy M, Humm J, Chaft J, Fredrickson J, Weber WA. Delayed 18F-FDG PET imaging can improve detection of lesions in patients with advanced non-small cell lung cancer. Annual Congress of the European Association of Nuclear Medicine 43(Suppl 1):S309, 2016. e-Pub 2016.
20. Krebs S, Dunphy M, Hyman D, Fornier M, Veach D, Larson S, Lyashchenko S, Zanzonico P, Lewis J, Weber WA. First-in-human trial of dasatinib-tracer PET imaging: preliminary results in cancer patients. ACNM Annual Meeting and SNMMI Mid-Winter Meeting, 2015.
21. Krebs S, Chow K, Yi Z, Brawley V, Ahmed N, Gottschalk S. T cells expressing IL13Rα2-specific chimeric antigen receptors based on IL13.E13K Muteins have potent anti-glioma activity but also recognize IL13Rα1+ cells. Pediatric Neuro-Oncology Basic and Translational Research Conference 15(Suppl):i1-i51, 2013. e-Pub 2013.
22. Krebs S, Chow K, Yi J, Brawley V, Ahmed N, Gottschalk S. T cells redirected to IL13Rα2 for glioblastoma immunotherapy. 3rd International Conference on Immunotherapy in Pediatric Oncology, 2012.
23. Krebs S, Trippel M, Prokop T, Omer TN, Landwehrmeyer B, Weber WA, Nikkhah G. Immune response after cerebral engraftment of human neuronal cells in patients with Huntington's disease. 20th Annual Meeting of the Network of European CNS Transplantation and Restoration, 2010.
24. Krebs S, Trippel M, Prokop T, Omer TN, Landwehrmeyer B, Weber WA, Nikkhah G. Immune response after cerebral engraftment of human neuronal cells in patients with Huntington's disease: Consequences for pediatric neuronal cell transplantation programs. 2nd International Conference on Immunotherapy in Pediatric Oncology, 2010. e-Pub 2010.
25. Krebs S, Trippel M, Prokop T, Omer TN, Landwehrmeyer B, Weber WA, Nikkhah G. HLA-antibodies after intrastriatal engraftment of human foetal neuronal cells in patients with Huntington's disease: Clinical course and consequences for immunosuppressive therapy. 10th Meeting of the Forum of European Neurosciences, 2008.